Figure 2.
![Figure 2. GSK activates TRPV4 sparklets in pial and parenchymal myocytes, but not in mesenteric myocytes. (A–C) Set of TIRF images showing representative male (left) and female (right) pial (A), parenchymal (B), and mesenteric (C) myocytes before (control) and after application of the TRPV4 channel agonist GSK (100 nM). Traces to the right of each image show the time course of [Ca2+]i in regions highlighted by green circles.](https://cdn.rupress.org/rup/content_public/journal/jgp/149/6/10.1085_jgp.201611709/6/jgp_201611709_fig2.jpeg?Expires=1771763802&Signature=RGIi4IOxLwcPWTQXvH-tasV1d1covAuxSxo6NihfSPV16-zIR7h8CtyyYfg0w4UMeo7XfbLoYIfrRfPDBNzgb4vqlDsp5p10u0t4ppQgVNWNKZS8hX4U-evRRXfBgm3U~sTVsfpoJVkftocJwFBqy0iKl13bO5NimJfRE3K9-wano5bVzel~U2DaWSWvUNUAul6gk1LAV8waoYmORI~VbO7jW3D3GEMZ8AtvCIkkNGIgKa~61DXiFU~7JjqYK6E1DGxSjd1vs3WOR3zmhPXYgkf5z0oTW2eIEK~EfqmhIDiTOXaqwuPrYlfeuBpA7I9pCajdGGpymUnuior3~6g61g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
GSK activates TRPV4 sparklets in pial and parenchymal myocytes, but not in mesenteric myocytes. (A–C) Set of TIRF images showing representative male (left) and female (right) pial (A), parenchymal (B), and mesenteric (C) myocytes before (control) and after application of the TRPV4 channel agonist GSK (100 nM). Traces to the right of each image show the time course of [Ca2+]i in regions highlighted by green circles.
